1 results match your criteria: "e Icahn School of Medicine at Mount Sinai and Mount Sinai St. Luke's[Affiliation]"
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.
J Dermatolog Treat
December 2017
e Icahn School of Medicine at Mount Sinai and Mount Sinai St. Luke's, New York , NY , USA.
Introduction: Scalp psoriasis adversely affects patients' lives and is often resistant to treatment; however, it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis.
Methods: A randomized, double-blind, placebo-controlled, multicenter study was conducted in 102 adult patients with moderate-to-severe scalp psoriasis.